EFFICACY OF SALBUTAMOL AND LASIX IN EARLY RESOLUTION OF TRANSIENT TACHYPNEA OF NEWBORN
Main Article Content
Keywords
Early Resolution, Lasix, Newborn, Salbutamol, Transient Tachypnea
Abstract
Objective: To determine the efficacy of Salbutamol and Lasix in early resolution of transient tachypnea in newborns.
Methodology:
It was a randomized clinical trial. The study was conducted in Combined Military Hospital (CMH) during the period between September 2023 and February 2024. In this study, we enrolled 120 neonates; they were randomly divided into two groups. Salbutamol (Group A), 0.20 ml 0.9% Salbutamol added to each nebulizer cap after a total of 2.5 ml; Lasix (Group B), Furosemide at a dose rate of 2 mg / kg. Both groups received the same basic treatment, which consisted of intravenous supplementation with fluids, parenteral nutrition, and supplementary oxygen as needed; analgesia for patient comfort, as requested; and appropriate antibiotic therapy. SPSS version 26.0 was used to analyze the data.
Results:
The average ages for the infants under Salbutamol and Lasix were 8.92 ± 5.24 and 10.55 ± 5.11 days, respectively. In the Salbutamol group, 41.7% were males, while 58.3% were females; in the Lasix group, 46.7% were males, compared to 53.3% female. The breathing rate for the Salbutamol versus Lasix groups was 32.55 ± 4.14 bpm versus 33.88 ± 3.79 bpm, respectively (p = 0.068); the heart rate was 114.83 ± 11.41 bpm versus 121.22 ± 17.83 bpm, respectively (p = 0.021). Oxygen saturation was 88.20 ± 3.89% and 86.53 ± 5.46% in the Salbutamol and Lasix groups, respectively (p = 0.057). The general blood count was 9.0 ± 4.21 cells/mcL for Salbutamol and 9.81 ± 4.57 cells/mcL for Lasix (p = 0.317). Blood sugar was 113.82 ± 21.35 mg/dL for Salbutamol as opposed to 124.20 ± 19.74 mg/dL for Lasix (p = 0.007).
Conclusion:
It is to be concluded that both Salbutamol and Lasix demonstrated notable impacts on key clinical markers and aided in managing transient tachypnea of the newborn. Salbutamol showcased advantages for certain parameters, while Lasix proved more efficacious for others. These discoveries imply that either drug serves as an effective therapeutic alternative, with treatment selection dependent on the patient's clinical presentation and response over time. Further investigation could optimize regimens and enhance neonatal prognosis moving forward.
References
2. Buchiboyina A, Jasani B, Deshmukh M, Patole S. Strategies for managing transient tachypnoea of the newborn-a systematic review. J Matern Fetal Neonat Med. 2017;30(13): 1524-32.
3. Al Lahony DM, Elsayed HM, Mohammed IS. The effects of inhaled β-adrenergic agonists in transient tachypnea of the newborn. Menoufia Med J. 2020;33(3):847-51.
4. Mussavi M, Asadollahi K, Kayvan M, Sadeghvand S. Effects of nebulized albuterol in transient tachypnea of the newborn a clinical trial. Iran J Ped. 2017;27(3).
5. Malakian A, Dehdashtian M, Aramesh MR, Aletayeb MH, Heidari S. The effect of inhaled salbutamol on the outcomes of transient tachypnea of the newborn. J Chinese Med Assoc. 2018;81(11):990-7.
6. Babaei H, Dabiri S, Pirkashani LM, Mohsenpour H. Effects of salbutamol on the treatment of transient tachypnea of the newborn. Iran J Neonatol. 2019;10(1).
7. Mohammadzadeh I, Akbarian-Rad Z, Heidari F, Zahedpasha Y, Haghshenas-Mojaveri M. The effect of inhaled salbutamol in transient of tachypnea of the newborn: a randomized clinical trial. Iran J Ped. 2017;27(5).
8. Yildiz R, Ok M. Clinical efficacy of combinations of nebulised fluticasone, salbutamol and furosemide on lung function in premature calves with respiratory distress syndrome. Vet Med. 2017;62(10):541-52.
9. Dehdashtian M, Malakian A, Aramesh MR, Mazori A, Aletayeb MH, Shirani A, et al. Effectiveness of intratracheal salbutamol in addition to surfactant on the clinical course of newborns with respiratory distress syndrome: a clinical trial. Italian J Ped. 2016;42:1-5.
10. Sabry AM, Azeem MA, Ismail MM, El Khatib DH, AbdelAziz IA. Comparison of inhaled salbutamol and intravenous furosemide in the treatment of transient tachypnea of the newborn regarding their safety and efficacy. Alexandria J Ped. 2022;35(2):92-8.
11. Yurdakok M, Ozek E. Transient tachypnea of the newborn: the treatment strategies. Curr Pharm Design. 2012;18(21):3046-9.
12. Anwar M, Ahmad M, Hussain A, Ali MA, Wase K, Ahmad M. Impact of inhaled salbutamol in transient tachypnea of newborn. Pak Postgrad Medical J. 2023;34(01):28-32.
13. Ahmed W, Tahir AM, Subhani FA, Ahmed Z, Sohail A, Javed H. Role of salbutamol in the management of transient tachypnea of the newborn: a comparative prospective study. Pak Armed Forces Med J. 2022;72(5):1501-05.
14. Buchiboyina A, Jasani B, Deshmukh M, Patole S. Strategies for managing transient tachypnoea of the newborn-a systematic review. J Matern Fetal Neonat Med. 2017;30(13):1524-32.
15. Basiri B, Sadeghi N, Sabzehei MK, Ashari FE. Effects of inhaled salbutamol on transient tachypnea of the newborn. Resp Care. 2022;67(4):433-9.
16. Salama AA, El-Seheimy LA, Elsamanoudy MI. Inhaled salbutamol for the treatment of transient tachypnea of the newborn. Int J Med Arts. 2020;2(2):457-61.
17. Khushdil A, Ahmed Z, Ahmed M, Nazir S, Waqar T. Effects of salbutamol and furosemide in the treatment of transient tachypnea of newborn-a randomized controlled trial. Pak Armed Forces Med J. 2022;72(1):101-04.
18. Armangil D, Yurdakök M, Korkmaz A, Yiğit Ş, Tekinalp G. Inhaled beta-2 agonist salbutamol for the treatment of transient tachypnea of the newborn. J Pediatr. 2011;159(3):398-403.
19. Ali S, Razzaq A, Shah SA, Ahmad Z. Intravenous furosemide in the management of transient tachypnea of newborn. Pak Armed Forces Med J. 2023;73(3):666-9.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Hina Muhammad Ali
Combined Military Hospital (CMH), Quetta DESIGNATION: Fellow Neonatal Paediatric
QUALIFICATION: MBBS, FCPS
Dr. Muhammad Adnan
AFFILIATION: King Abdullah Specialized Children Hospital, Riyadh DESIGNATION: Staff Physician Pediatric QUALIFICATION: MBBS, Diploma In Pediatrics (Ireland)
Ehtisham Hussain
AFFILIATION: Sindh Institute Of Child Health And Neonatology (SICHN), Karachi
DESIGNATION: Fellow Neonatal Medicine QUALIFICATION: MBBS, FCPS
Dr. Abeer Asif
AFFILIATION: Combined Military Hospital, Quetta DESIGNATION: Assistant Professor
QUALIFICATION: MBBS, FCPS (Paeds Med), FCPS (Neonat Paed)
Lt Col Muhammad Shoaib
AFFILIATION: Combined Military Hospital, Quetta DESIGNATION: Senior Registrar
QUALIFICATION: MBBS, FCPS
Dr. Samrina Yasmin
AFFILIATION: Combined Military Hospital, Quetta DESIGNATION: Postgraduate Trainee
QUALIFICATION: MBBS
Dr. Syed Moeed
AFFILIATION: Combined Military Hospital, Quetta
DESIGNATION: Fellow Neonatal Paediatric QUALIFICATION: MBBS, FCPS